[go: up one dir, main page]

PE20080150A1 - Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch) - Google Patents

Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch)

Info

Publication number
PE20080150A1
PE20080150A1 PE2007000677A PE2007000677A PE20080150A1 PE 20080150 A1 PE20080150 A1 PE 20080150A1 PE 2007000677 A PE2007000677 A PE 2007000677A PE 2007000677 A PE2007000677 A PE 2007000677A PE 20080150 A1 PE20080150 A1 PE 20080150A1
Authority
PE
Peru
Prior art keywords
aril
mch
antagonists
receptor
halo
Prior art date
Application number
PE2007000677A
Other languages
English (en)
Inventor
Manuel Jesus Alcazar-Vaca
Jacqueline Macritchie
Jose Ignacio Andres-Gil
Santamarina Julen Oyarzabal
Frank Matthias Dautzenberg
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20080150A1 publication Critical patent/PE20080150A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PIRIDINONA N-ARIL Y N-HETEROARIL SUSTITUIDOS DE FORMULA (I) DONDE A ES FENILO O PIRIDINILO; R1 Y R2 SON CADA UNO H, ALQUILO(C1-C3), ALQUILCARBONILO(C1-C3), ALQUILOXI(C1-C3)-ALQUILO(C1-C3), ENTRE OTROS; R3 ES H, HALO, CN, OH, OXO, ENTRE OTROS; R4 Y R5 SON CADA UNO H, HALO, CN, OH, AMINO, ENTRE OTROS; k Y l SON CADA UNO DE 0 A 4; m ES DE 0 A 3; Y1 E Y3 SON CADA UNO UN ENLACE SIMPLE, NR7, O, S, SO O SO2, DONDE R7 ES H O ALQUILO(C1-C3); Y2 ES UN HIDROCARBURO(C1-C6) OPCIONALMENTE SUSTITUIDO CON HALO, CN, OH, AMINO, TIO, ENTRE OTROS; B ES UN ANILLO DE 6 MIEMBROS QUE TIENE HASTA 3 ATOMOS DE N OPCIONALMENTE SUSTITUIDO CON HALO, CN, OH, OXO, TIO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS LOS COMPUESTOS DE FORMULA (i), (ii), ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE LA HORMONA CONCENTRADORA DE MELANINA (MCH) SIENDO UTILES EN EL TRATAMIENTO DE ANSIEDAD, DEPRESION, PSICOSIS
PE2007000677A 2006-06-02 2007-05-31 Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch) PE20080150A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06114917 2006-06-02
EP06123263 2006-10-31

Publications (1)

Publication Number Publication Date
PE20080150A1 true PE20080150A1 (es) 2008-04-11

Family

ID=38266244

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000677A PE20080150A1 (es) 2006-06-02 2007-05-31 Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch)

Country Status (5)

Country Link
AR (1) AR061163A1 (es)
PE (1) PE20080150A1 (es)
TW (1) TW200811146A (es)
UY (1) UY30378A1 (es)
WO (1) WO2007141200A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008041090A1 (en) * 2006-10-06 2008-04-10 Pfizer Limited Malanin concentrating hormone receptor-1 antagonist pyridinones
CA2727055C (en) 2008-01-11 2016-12-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
US8278316B2 (en) 2009-03-09 2012-10-02 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
EP2437599A4 (en) * 2009-06-03 2012-10-31 Glaxosmithkline Llc BIS-PYRIDYLPYRIDONE AS MELANIN CONCENTRATION HORMONE RECEPTOR-1 ANTAGONISTS
WO2010141545A1 (en) * 2009-06-03 2010-12-09 Glaxosmithkline Llc Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
EP2448585B1 (en) * 2009-07-01 2014-01-01 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011127643A1 (en) * 2010-04-12 2011-10-20 Merck Sharp & Dohme Corp. Pyridone derivatives
EP2558094A4 (en) * 2010-04-12 2013-09-25 Merck Sharp & Dohme pyridone derivatives
US9359300B2 (en) 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
DK2648516T3 (da) 2010-12-06 2019-01-02 Aclaris Therapeutics Inc Substituerede pyridinon-pyridinylforbindelser
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
WO2013149362A1 (en) * 2012-04-06 2013-10-10 Glaxosmithkline Llc 1-(dihydronaphthalenyl)pyridones as melanin-concentrating hormone receptor 1 antagonists
KR102057877B1 (ko) 2012-07-18 2019-12-20 노스 앤드 사우스 브라더 파마시 인베스트먼트 컴파니 리미티드 질소함유 헤테로고리 유도체 및 그의 약물에서의 용도
RS61724B1 (sr) 2013-06-07 2021-05-31 Aclaris Therapeutics Inc Metil/fluoro-piridinil-metoksi supstituisana piridinon-piridinil jedinjenja i fluoro-pirimidinil-metoksi supstituisana piridinon-piridinil jedinjenja
JP6454348B2 (ja) 2013-12-19 2019-01-16 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 窒素複素環誘導体およびその医薬品への応用
CN107698499A (zh) * 2016-08-08 2018-02-16 罗楹 一种羟尼酮的制备方法
CN116023327A (zh) * 2016-08-08 2023-04-28 北京康蒂尼药业股份有限公司 一种羟尼酮的制备方法
JP2023509800A (ja) * 2020-01-10 2023-03-09 コンシナンス セラピューティクス， インコーポレイテッド 薬物の治療的組み合わせ及びそれらの使用方法
JP2023519891A (ja) 2020-03-27 2023-05-15 アクラリス セラピューティクス，インコーポレイテッド 置換ピリジノン－ピリジニル化合物のプロセス、組成物、および結晶形態

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1490064E (pt) * 2002-02-14 2009-12-28 Pharmacia Corp Piridinonas substituídas como moduladores de p38 map-quinase
US7732456B2 (en) * 2004-03-05 2010-06-08 Banyu Pharmaceutical Co., Ltd. Pyridone derivative
WO2007024004A1 (ja) * 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体

Also Published As

Publication number Publication date
WO2007141200A1 (en) 2007-12-13
WO2007141200A8 (en) 2008-03-27
AR061163A1 (es) 2008-08-06
TW200811146A (en) 2008-03-01
UY30378A1 (es) 2008-01-02

Similar Documents

Publication Publication Date Title
PE20080150A1 (es) Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch)
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20120135A1 (es) Piperidinas sustituidas como antagonistas de ccr3
AR061644A1 (es) Derivados de benzofurano
PE20081887A1 (es) Nuevo compuesto de adenina
PE20080855A1 (es) Derivados de pirazina-2-carboxamida
PE20130155A1 (es) Derivados de ariletinilo
PE20110409A1 (es) Compuestos heterociclicos antiviricos
PE20090775A1 (es) Nuevos derivados de biarilo
PE20160431A1 (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica
PE20130279A1 (es) Compuestos heteroarilo nitrogenados
PE20071245A1 (es) COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs)
PE20080889A1 (es) Aminometil-4-imidazoles
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
ECSP099461A (es) Compuesto heteromonocíclico y uso del mismo
AR072753A1 (es) Derivados de oxazina como inhibidores de 11 beta - hidroxiesteroiode deshidrogenasa 1
AR063684A1 (es) Derivados de 4, 4´-bifenildiilbis(1h-imidazol-5, 2-diil) como inhibidores del virus de la hepatitis c, composicion que los comprende y su uso para tratar una infeccion con vhc.
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR064735A1 (es) Agonistas de gpcr y composicion farmaceutica en base al compuesto
CO5580788A2 (es) Compuestos de bencimidazol sustituidos utiles como inhibidores de proteina cinasas
AR060535A1 (es) Pirido-piridazinonas y ftalazinonas como antagonistas duales de los receptores h1 y h3 de histamina
PE20151060A1 (es) Nuevos derivados de pirazina como agonistas del receptor cb2
AR068115A1 (es) Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida
CL2012000516A1 (es) Compuestos derivados de 3-[4-(4-(fenil/piridin/ pirimidin)- piperazin -1-il)-butil]-2, 3-dihidro-4h-croman-4-ona, moduladores del receptor de dopamina d3; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de un desorden neurologico o psiquiatrico, disfuncion erectil o dependencia a drogas, entre otros.

Legal Events

Date Code Title Description
FC Refusal